SEARCH

SEARCH BY CITATION

References

  • 1
    Larsson H, Carlsson E, Mattson H, et al. Plasma gastrin and enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391 9.
  • 2
    Hakanson R, Böttcher G, Sundler F, et al. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion 1986; 35(Suppl. 1): 42 55.
  • 3
    Creutzfeldt W. The achlorhydria-carcinoid sequence. Role of Gastrin. Digestion 1988; 39: 61 79.
  • 4
    Hakanson R & Sundler F. Proposed mechanism of induction of gastric carcinoids: The gastrin hypothesis. Eur J Clin Invest 1990; 20(Suppl. 1): 65 71.
  • 5
    Hakanson R, Chen D, Tielemans Y, et al. ECL cells: biology and pathobiology. Digestion 1994; 55(Suppl. 3): 38 45.
  • 6
    Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35: 42 55.
  • 7
    Havu N, Mattsson H, Ekman L, et al. Enterochromaffin cell carcinoids in rat gastric mucosa following long-term administration of ranitidine. Digestion 1990; 45: 189 95.
  • 8
    Tielemans Y, Hakanson R, Sundler F, et al. Proliferation of enterochromaffin-like cells in omeprazole treated hypergastrinernic rats. Gastroenterology 1989; 96: 723 9.
  • 9
    Solcia E, Rindi G, Havu N, et al. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol1989; 24(Suppl. 66): 129 137.
  • 10
    Creutzfeldt W & Lamberts R, et al. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion 1992; 51(Suppl. 1): 76 81.
  • 11
    Solcia E, Capella C, Fiocca, et al. Gastric argyrophil carcinoidosis in patients with Zollinger–Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990; 14: 503 13.
  • 12
    Lehy T, Cadiot G, Mignon M, et al. Influence of multiple endocrine neoplasia type-1 on gastric endocrine cells in patients with the Zollinger–Ellison syndrome. Gut 1992; 33: 1275 9.
  • 13
    Lehy T, Mignon M, Cadiot G, et al. Gastric endocrine cell behaviour in ZollingerEllison patients upon long-term potent antisecretory treatment. Gastroenterology 1989; 96: 1029 40.
  • 14
    Carney JA, Go VWL, Fairbanks, et al. The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Intern Med 1983; 99: 761 6.
  • 15
    Bordi C, Pilato F, Carfagna G, et al. Argyrophil cell hyperplasia of flandic mucosa in patients with chronic atrophic gastritis. Digestion 1986; 35 (Suppl. 1): 130 43.
  • 16
    Borch K, Renvall H, Liedberg G, et al. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88: 638 48.
  • 17
    Solcia E, Fiocca R, Villani L, et al. Morphology and natural history of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterol 1991; 26(Suppl. 180): 146 59.
  • 18
    Chandrasekharappa S, Guru S, Manickarn P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276(5311): 404 7.
  • 19
    Solcia E, Rindi G, Fiocca R, et al. Distinct patterns of chronic gastritis associated with carcinoid, neuroendocrine carcinoma or ordinary cancer and their role in tumorigenesis. Yale J Biol Med 1992; 65: 793 804.
  • 20
    Bordi C, D’adda T, Azzoni C, et al. Hypergastrinemia and Gastric Enterochromaffin like Cells. Am J Surg Pathol 1995; 19(Suppl. 1): S8 S19.
  • 21
    Lamberts R, Creutzfeldt W, Stockmann F, et al. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988; 39: 126 35.
  • 22
    Lamberts R, Creutzfeldt W, Strüber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology 1993; 104: 1356 70.
  • 23
    Klinkenberg-Knol E, Festen H, Jansen J, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Int Med 1994; 121(3): 161 7.
  • 24
    Penston JG, Dixon JS, Selway SAM, et al. Gastric histology and plasma gastrin response to a meal in patients with duodenal ulcer disease after five years treatment with ranitidine. Aliment Pharmacol Ther 1990; 4: 381 92.
  • 25
    Kuipers EJ, Uyterlinde AM, Pena S, et al. Increase of Helicobacter-pylori-associated corpus gastritis during acid-suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90(9): 1401 6.
  • 26
    Kuipers EJ, Lundell L, Klinkenberg-Knol E, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018 22.
  • 27
    Solcia E, Villani L, Luinetti 0, et al. Proton pump inhibitors, enterochromaffin-like cell growth and Helicobacter pylori gastritis . Aliment Pharmacol Ther 1993; 7(Suppl. 1): 25 8.
  • 28
    El-Nujumi A, Williams C, McColl KEL, et al. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut 1998; 42: 159 65.
  • 29
    Eissele P, Brunner G, Simon B, et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia . Gastroenterology 1997; 112: 707 17.
  • 30
    Waldum BL, Brenna E, Kleveland PM, et al. Review article: the use of gastric acid inhibitory drugs-physiological and pathophysiological considerations. Aliment Pharmacol Ther 1993; 7: 589 96.
  • 31
    Waldum M, Brenna E, Kleveland PM, et al. Gastrin-physiological and pathophysiological role: clinical consequences. Dig Dis 1995; 13: 25 38.
  • 32
    Waldum BL, Haugen OA, Isaksen R, et al. Enterochromaffin-like cells in the diffuse but not the intestinal type of gastric carcinomas. Scand J Gastroenterol 1991; 26(Suppl. 180): 165 9.
  • 33
    Modlin I, Lawton G, Miu K, et al. Pathophysiology of the fundic enterochromaffin-like (ECL) cell and gastric carcinoid tumours. Ann R Coll Surg Engl 1996; 78: 133 8.
  • 34
    O’connor D & Deftos LS. Secretion of chromogranin A by peptide producing endocrine cell. N Engl J Med 1986; 314: 1145 51.
  • 35
    Stridsberg M, Hellman U, Wilander E, et al. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours. Development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993; 139: 329 37.
  • 36
    Stridsberg M, Oberg K, Li Q, et al. Measurement of chromogranin A, chromogranin B (secretogranin 1), chromogranin C (secretogranin 11) and pancreastatin in plasma and urine of patients with carcinoid tumours. J Endocrinol 1995; 144: 49 59.
  • 37
    Fahrenkamp AG, Wibbeke Q, Winde G, et al. Immunohistochemical distribution of chromogranins A and B and secretogranin 11 in neuroendocrine tumours of the gastrointestinal tract. Virchows Arch 1995; 426: 361 7.
  • 38
    Oberg K. Neuroendocrine gastrointestinal tumors—Review. Ann Oncol 1996; 7: 453 563.
  • 39
    Stabile B, Howard T, Pasaro E, et al. Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg 1990; 125: 451 3.
  • 40
    Syversen U, Mignon M, Bonfils S, et al. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncologica 1993; 32(2): 161 5.
  • 41
    Borch K, Stridsberg M, Burman P, et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32: 198 202.
  • 42
    Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after orneprazole treatment. Gut 1996; 39: 649 53.
  • 43
    Houben P, Lundqvist G, Biemond I, et al. Twenty-four-hour intragastric pH, basal and meal-stimulated serum gastrin, and plasma chromogranin A after short-term acid inhibition. Gastroenterology 1997; 112(4): A152.
  • 44
    Bonten M, Gaillard C, Stockbrügger R, et al. Assessment of gastric acidity in intensive care patients: intermittent pH registration cannot replace continuous pH monitoring. Intensive Care Med 1996; 22(3): 220 5.
  • 45
    Jansen J & Lamers C. Effect of changes in serum calcium on secretin-stimulated serum gastrin in patients with Zollinger–Ellison syndrome. Gastroenterol 1982; 83: 173 8.
  • 46
    Mc Cloy RF, Arnold I, Bardhan, Kd, et al. Pathophysiological effects of long-term acid suppression in man. Digestive Dis Sci 1995; 40(2): 96S 120S.
  • 47
    Leth R, Olbe L, Haglund U, et al. The pentagastrin-induced gastric acid response in humans. Scand J Gastroenterol 1988; 23: 224 48.
  • 48
    Waldum H, Sandvik A, Brenna E, et al. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut 1991; 32: 698 701.
  • 49
    Hakanson R & Sundler F. Do histamine-storing cells in the gastric mucosa mediate the acid-stimulating action of gastrin? Handbook Exp Pharm 1991; 97: 325 46.
  • 50
    Yogeshar D. Hyperplastic Proliferations of the ECL cells. Yale J Biol Med 1992; 65: 805 25.
  • 51
    Driman DK, Wright C, Tougas G, et al. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Digestive Dis Sci 1996; 41(10): 2039 47.
  • 52
    Lind T, Cederberg C, Forssell H, et al. Relationship between reduction of acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988; 23: 1259 66.
  • 53
    Jansen J, Klinkenberg-Knol E, Meuwissen S, et al. Effects of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990; 99: 621 8.
  • 54
    Hendy GN, Bevan S, Mattei MG, et al. Chromogranin A. Clin Invest Med 1995; 18: 47 65.
  • 55
    Lewis JJ, Mon MJ, Adrian TE, et al. Pancreastatin: a novel peptide inhibitor of parietal cell secretion. Surgery 1988; 104: 1031 6.